Cormorant Capital
VC Fund
New York, United States
Cormorant Capital is a VC fund in New York focused on Biotechnology and Health Care. Cormorant Capital facilitates the growth of real estate-operator and owner clients by co-investing in select transactions. Cormorant Capital was established to respond to such equity needs, while maintaining alignment of interests between partners. Such alignment is accomplished not only through balanced joint-venture economics, but also byidentifying owner/operator value-add in specific products and geographies sought after by investors.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Cormorant Capital invests in
BiotechnologyHealth CareMedicalPharmaceuticalLife Science
Stages Cormorant Capital invests in
Series BSeries CSeries DSeries APrivate Equity
Countries Cormorant Capital invests in
United StatesChinaSwitzerland
Investment Focus
Industry
- Biotechnology 9 (75%)
- Health Care 6 (50%)
- Medical 5 (42%)
- Pharmaceutical 4 (33%)
- Life Science 3 (25%)
Stage
- Series B 4 (33%)
- Series C 3 (25%)
- Series D 2 (17%)
- Series A 1 (8%)
- Private Equity 1 (8%)
Country
- United States 9 (75%)
- China 1 (8%)
- Switzerland 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Terremoto Biosciences
|
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. | $175M / Series B / Nov 02, 2023 | |
Freenome
|
Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $300M / Series D / Dec 07, 2021 | |
Shoreline Biosciences
|
Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients. Its proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cellsto improve anti-cancer activity. The company was founded in 2020 and is headquartered in La Jolla, CA, USA. | $43M / Series A / Feb 07, 2021 | |
Prometheus Biosciences
|
Prometheus Biosciences, Inc., former Prometheus Laboratories, Inc., a specialty pharmaceutical company, engages in developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. It markets and promotes Entocort EC, a glucocorticosteroid, which is indicated for the induction and maintenanceof clinical remission in mild to moderately active Crohn's disease involving the ileum and/or the ascending colon. It has an agreement to acquire rights to LOTRONEX tablets, which is used in female patients with diarrhea-predominant irritable bowel syndrome; and an agreement to develop and commercialize COLAL-PRED, a development-stage product for the treatment of gastrointestinal diseases or other applications. The company also sells other branded drugs, including Imuran for use as an adjunct for the prevention of rejection in kidney transplantation and the management of active rheumatoid arthritis, Helidac Therapy for use together with an H2 antagonist for the eradication of helicobacter pylori bacteria, and Ridaura for the management of rheumatoid arthritis. In addition, Prometheus Laboratories sells a generic formulation of mercaptopurine, which is approved as maintenance therapy for acute lymphatic leukemia as part of a combination regimen through third-party distributors. Further, it provides diagnostic testing services, including specific immunoassays to detect and differentiate diseases, pharmacogenetic testing, and drug metabolite monitoring; and tests that assist physicians in using and monitoring thiopurine drugs and the detection, diagnosis, or treatment of celiac disease, lactose intolerance, and other related disorders. Prometheus Laboratories, Inc. was founded in 1995 and is headquartered in San Diego, California. | $130M / Private Equity / Nov 09, 2020 | |
VectivBio
|
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and theirfamilies, not just provide an incremental improvement or benefit over the standard-of-care.It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland. | $110M / Venture - Series Unknown / Oct 19, 2020 | |
Everest Medicines
|
Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in the Emerging Market including Asia Pacific territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients inthe Emerging Market and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in Asia Pacific territories and with leading global pharmaceutical companies. | $310M / Series C / Jun 03, 2020 | |
Revolution Medicines
|
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.REVOLUTION Medicines builds upon the vision of the company’s founder, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois atUrbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute, who invented a transformative method for synthesizing original compounds that are pharmaceutically optimized analogues of complex natural products. REVOLUTION Medicines has entered into an exclusive license agreement with the University of Illinois to practice and expand this technology.REVOLUTION Medicines’ approach is a rapid, standardized and powerful process for assembling simple “chemical building blocks” into refined natural product-like structures. These optimized compounds have significant potential as best-in-class drug candidates. | $100M / Series C / Jul 09, 2019 | |
Satsuma Pharmaceuticals
|
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasaldelivery device. | $62M / Series B / Apr 24, 2019 | |
BridgeBio
|
BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. | $299.2M / Series D / Jan 23, 2019 | |
Cabaletta Bio
|
Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. The company's therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that bind and destroy only disease-causing B cells while sparing healthy Bcells which are essential for human health. Cabaletta has signed an exclusive licensing agreement and partnership with Penn focused on treating B cell-mediated autoimmune diseases with CAAR T cells. Cabaletta was founded by Dr. Michael Milone, Dr. Aimee Payne and Dr. Steven Nichtberger. Dr. Milone and Dr. Payne are physicians/scientists at Penn and also serve as co-chairs of Cabaletta’s Scientific Advisory Board. The Company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus Vulgaris (mPV). mPV is a rare skin disorder that causes painful blisters and sores on mucous membranes such as the mouth, nose, throat, and genitals, leading to severe and sometimes debilitating and life-altering effects. | $50M / Series B / Jan 03, 2019 | |
| See all 12 investments → | |||
Co-Investors
Eventide
4 deals together
Perceptive Advisors
4 deals together
Boxer Capital
3 deals together
Janus Henderson Investors
3 deals together
OrbiMed
3 deals together
RA Capital Management
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Life Science Investors
6,823 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does Cormorant Capital invest in?
Cormorant Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Cormorant Capital last invest?
The most recent investment recorded for Cormorant Capital closed in Nov 2023. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
